Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Colo. , Dec. 15, 2014  The Government of ... collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT to ... , as well as provide long-term health system capacity to ... Facts: , The Ghanaian Ebola Readiness and Resilience Initiative ... Ghana,s preparations for the possible arrival of the ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/2r6bmg/drug_injection ... "Drug Injection Devices to 2020" report to ... As new drugs become available ... health conditions, drug developers have increasingly pursued packaging ... and increase the efficiency and reliability with which ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha ... the HiSeq X Ten sequencing system manufactured by ... HudsonAlpha to produce and analyze genomic data faster ... from the Institute,s commitment to research programs for ... HiSeq X Ten provides unprecedented capacity, speed and ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Overactive Bladder Treatment for... -- ARDEE, Ireland, Oct. 18 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Medicine Technology:Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 2Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 3Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 4Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 5Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 6Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 7Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 8Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 9Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 2Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 3Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 4Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 5Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 6Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 7Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 8
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... pilots process visual information more efficiently than less experienced ... landings, a new study shows. Landing is one ... and 36 percent of all airplane crashes and 25 ... landing. Researchers monitored the brain activity of eight ... were at the controls of a flight simulator. As ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... molecules found in certain plants appears to have a beneficial ... a new study conducted in mice. The study was led ... Medical Center. An article in the Journal of Cellular and ... of the senior authors of the study, is available to ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin ... of healthcare related disinfectants in China,announced today ... Hi-Tech Company, Ltd., (LiKang Disinfectant) began training,and ... Olympics. The project,is sponsored by and under ...
... to Provide ... for Their Families, CHICAGO, May 7 Mother,s Day is ... gatherings and gifts,and to honor those who give so much to their families ... of those mothers who,live in poverty and need the assistance of programs offered ...
... Emory Winship Cancer Institute, ATLANTA, May 7 ... commitment of $50,000 to the Emory Winship Cancer ... southeast focused on,triple-negative breast cancer research. Dan Amos, ... president, made the personal donation,in honor of the ...
... The Female Health Company,(Amex: FHC ) today ... discuss its operating results for the second quarter of ... 14, 2008. The Company plans to,report its second quarter ... and other interested parties may participate in the,conference call ...
... Highlighted, TAMPA, Fla., May 7 Acute pain ... than 25 million,Americans are said to experience acute pain ... a recent study estimated that 42 percent of U.S.,hospital ... Seven clinical presentations on tapentadol immediate release (IR),tablets for ...
Cached Medicine News:Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 2Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 3Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 4Health News:Catholic Charities Calls for Increased Support of Mothers in Need: 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 3Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 4
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: